Peptide CDMO Pharmaceutical - Global and China Top Players Market Share and Ranking 2024
- Report Code : AMP2756649
- Published On: Jul, 2024
- Category : Healthcare & Pharma
- Pages : 163
-
According to Ample Market Research, the global market for Peptide CDMO Pharmaceutical should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.
By country, China accounted for percent of the global market last year and China’s market share increased from percent to percent. China Peptide CDMO Pharmaceutical market should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030. The United States Peptide CDMO Pharmaceutical market should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.
By segment, Peptide Supplements grew percent to account for percent of the total market sales, and Peptide Vaccines grew percent.
This report studies and analyses global Peptide CDMO Pharmaceutical status and future trends, to help determine the Peptide CDMO Pharmaceutical market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Peptide CDMO Pharmaceutical, and provides market size (US$ million) and Year-over-Year growth, considering 2024 as the base year.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
To assess the competitive environment within the market including supplier revenue, market share, and company profiles.
Highlights
(1) Global Peptide CDMO Pharmaceutical market size, history data 2019-2024, and forecast data 2024-2030, (US$ million)
(2) Global Peptide CDMO Pharmaceutical by company, revenue, market share and industry ranking 2019-2024, (US$ million)
(3) China Peptide CDMO Pharmaceutical by company, revenue, market share and industry ranking 2019-2024, (US$ million)
(4) Global Peptide CDMO Pharmaceutical key consuming regions, consumption value and demand structure
(5) Peptide CDMO Pharmaceutical industry chains, upstream, midstream and downstream
Market segment by players, this report covers
Ambiopharm
Auspep
Bachem
Bcn Peptide
Cpc Scientific
Creative Peptides
Chinese Peptide
Csbio
Corden Pharma
Polypeptide
Hybio Pharmaceutical
Peptide Institute
Pepscan
Almac
Vivitide
Creosalus Inc
Scinopharm
Senn Chemicals
Belyntic
Ferring Pharma
Numaferm
Hybio Pharmaceutical
Provepharm Life Solutions
Enzene Biosciences
Piramal Pharma
Market segment by Type, covers
Liquid-phase Peptide Synthesis（LPPS）
Solid-phase Peptide Synthesis（SPPS）
Mixed Phase
Market segment by Application, can be divided into
Peptide Supplements
Peptide Vaccines
Others
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Peptide CDMO Pharmaceutical product scope, global consumption value, China consumption value, development opportunities, challenges, trends, and policies.
Chapter 2: Global Peptide CDMO Pharmaceutical market share and ranking of major manufacturers, revenue, 2019-2024
Chapter 3: China Peptide CDMO Pharmaceutical market share and ranking of major manufacturers, revenue, 2019-2024
Chapter 4: Peptide CDMO Pharmaceutical industry chain, upstream, medium-stream, and downstream.
Chapter 5: Segment by Type, consumption value, percent & CAGR, 2019-2030
Chapter 6: Segment by Application, consumption value, percent & CAGR, 2019-2030
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2019-2030
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2019-2030
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin.
Chapter 10: Conclusions
-
With tables and figures helping analyze worldwide Peptide CDMO Pharmaceutical Global and China Top Players market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
1 Market Overview1.1 Peptide CDMO Pharmaceutical Definition
1.2 Global Peptide CDMO Pharmaceutical Market Size and Forecast
1.3 China Peptide CDMO Pharmaceutical Market Size and Forecast
1.4 China Percentage in Global Market
1.5 Peptide CDMO Pharmaceutical Market Size: China VS Global Growth Rate, 2019-2030
1.6 Peptide CDMO Pharmaceutical Market Dynamics
1.6.1 Peptide CDMO Pharmaceutical Market Drivers
1.6.2 Peptide CDMO Pharmaceutical Market Restraints
1.6.3 Peptide CDMO Pharmaceutical Industry Trends
1.6.4 Peptide CDMO Pharmaceutical Industry Policy
2 Global Leading Players and Market Share2.1 By Revenue of Peptide CDMO Pharmaceutical, Global Market Share by Company, 2019-2024
2.2 Global Peptide CDMO Pharmaceutical Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Peptide CDMO Pharmaceutical Concentration Ratio
2.4 Global Peptide CDMO Pharmaceutical Mergers & Acquisitions, Expansion Plans
2.5 Global Peptide CDMO Pharmaceutical Major Companies Product Type
2.6 Head Office and Peptide CDMO Pharmaceutical Production Site of Key Manufacturer
3 China Leading Players, Market Share and Ranking3.1 By Revenue of Peptide CDMO Pharmaceutical, China Market Share by Company, 2019-2024
3.2 China Peptide CDMO Pharmaceutical Participants, Market Position (Tier 1, Tier 2, and Tier 3)
4 Industry Chain Analysis4.1 Peptide CDMO Pharmaceutical Industry Chain
4.2 Peptide CDMO Pharmaceutical Upstream Analysis
4.2.1 Peptide CDMO Pharmaceutical Core Raw Materials
4.2.2 Main Manufacturers of Peptide CDMO Pharmaceutical Core Raw Materials4.3 Midstream Analysis
4.4 Downstream Analysis
4.5 Peptide CDMO Pharmaceutical Production Mode
4.6 Peptide CDMO Pharmaceutical Procurement Model
4.7 Peptide CDMO Pharmaceutical Industry Sales Model and Sales Channels
4.7.1 Peptide CDMO Pharmaceutical Sales Model
4.7.2 Peptide CDMO Pharmaceutical Typical Distributors
5 Sights by Type5.1 Peptide CDMO Pharmaceutical Classification
5.1.1 Liquid-phase Peptide Synthesis（LPPS）
5.1.2 Solid-phase Peptide Synthesis（SPPS）
5.1.3 Mixed Phase5.2 By Type, Global Peptide CDMO Pharmaceutical Consumption Value & CAGR, 2019 VS 2024 VS 2030
5.3 By Type, Global Peptide CDMO Pharmaceutical Consumption Value, 2019-2030
6 Sights by Application6.1 Peptide CDMO Pharmaceutical Segment by Application
6.1.1 Peptide Supplements
6.1.2 Peptide Vaccines
6.1.3 Others6.2 By Application, Global Peptide CDMO Pharmaceutical Consumption Value & CAGR, 2019 VS 2024 VS 2030
6.3 By Application, Global Peptide CDMO Pharmaceutical Consumption Value, 2019-2030
7 Sales Sights by Region7.1 By Region, Global Peptide CDMO Pharmaceutical Consumption Value, 2019 VS 2024 VS 2030
7.2 By Region, Global Peptide CDMO Pharmaceutical Consumption Value, 2019-2030
7.3 North America
7.3.1 North America Peptide CDMO Pharmaceutical & Forecasts, 2019-2030
7.3.2 By Country, North America Peptide CDMO Pharmaceutical Market Size Market Share7.4 Europe
7.4.1 Europe Peptide CDMO Pharmaceutical Market Size & Forecasts, 2019-2030
7.4.2 By Country, Europe Peptide CDMO Pharmaceutical Market Size Market Share7.5 Asia Pacific
7.5.1 Asia Pacific Peptide CDMO Pharmaceutical Market Size & Forecasts, 2019-2030
7.5.2 By Country/Region, Asia Pacific Peptide CDMO Pharmaceutical Market Size Market Share7.6 South America
7.6.1 South America Peptide CDMO Pharmaceutical Market Size & Forecasts, 2019-2030
7.6.2 By Country, South America Peptide CDMO Pharmaceutical Market Size Market Share
7.7 Middle East & Africa
8 Sales Sights by Country Level8.1 By Country, Global Peptide CDMO Pharmaceutical Market Size & CAGR, 2019 VS 2024 VS 2030
8.2 By Country, Global Peptide CDMO Pharmaceutical Consumption Value, 2019-2030
8.3 U.S.
8.3.1 U.S. Peptide CDMO Pharmaceutical Market Size, 2019-2030
8.3.2 By Type, U.S. Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 2030
8.3.3 By Application, U.S. Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 20308.4 Europe
8.4.1 Europe Peptide CDMO Pharmaceutical Market Size, 2019-2030
8.4.2 By Type, Europe Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 2030
8.4.3 By Application, Europe Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 20308.5 China
8.5.1 China Peptide CDMO Pharmaceutical Market Size, 2019-2030
8.5.2 By Type, China Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 2030
8.5.3 By Application, China Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 20308.6 Japan
8.6.1 Japan Peptide CDMO Pharmaceutical Market Size, 2019-2030
8.6.2 By Type, Japan Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 2030
8.6.3 By Application, Japan Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 2030
8.7 South Korea
8.7.1 South Korea Peptide CDMO Pharmaceutical Market Size, 2019-2030
8.7.2 By Type, South Korea Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 2030
8.7.3 By Application, South Korea Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 2030
8.8 Southeast Asia
8.8.1 Southeast Asia Peptide CDMO Pharmaceutical Market Size, 2019-2030
8.8.2 By Type, Southeast Asia Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 2030
8.8.3 By Application, Southeast Asia Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 2030
8.9 India
8.9.1 India Peptide CDMO Pharmaceutical Market Size, 2019-2030
8.9.2 By Type, India Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 2030
8.9.3 By Application, India Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 20308.10 Middle East & Africa
8.10.1 Middle East & Africa Peptide CDMO Pharmaceutical Market Size, 2019-2030
8.10.2 By Type, Middle East & Africa Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 2030
8.10.3 By Application, Middle East & Africa Peptide CDMO Pharmaceutical Consumption Value Market Share, 2024 VS 2030
9 Company Profile9.1 Ambiopharm
9.1.1 Ambiopharm Company Information, Head Office, Market Area and Industry Position
9.1.2 Ambiopharm Company Profile and Main Business
9.1.3 Ambiopharm Peptide CDMO Pharmaceutical Models, Specifications and Application
9.1.4 Ambiopharm Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.1.5 Ambiopharm Recent Developments9.2 Auspep
9.2.1 Auspep Company Information, Head Office, Market Area and Industry Position
9.2.2 Auspep Company Profile and Main Business
9.2.3 Auspep Peptide CDMO Pharmaceutical Models, Specifications and Application
9.2.4 Auspep Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.2.5 Auspep Recent Developments9.3 Bachem
9.3.1 Bachem Company Information, Head Office, Market Area and Industry Position
9.3.2 Bachem Company Profile and Main Business
9.3.3 Bachem Peptide CDMO Pharmaceutical Models, Specifications and Application
9.3.4 Bachem Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.3.5 Bachem Recent Developments9.4 Bcn Peptide
9.4.1 Bcn Peptide Company Information, Head Office, Market Area and Industry Position
9.4.2 Bcn Peptide Company Profile and Main Business
9.4.3 Bcn Peptide Peptide CDMO Pharmaceutical Models, Specifications and Application
9.4.4 Bcn Peptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.4.5 Bcn Peptide Recent Developments9.5 Cpc Scientific
9.5.1 Cpc Scientific Company Information, Head Office, Market Area and Industry Position
9.5.2 Cpc Scientific Company Profile and Main Business
9.5.3 Cpc Scientific Peptide CDMO Pharmaceutical Models, Specifications and Application
9.5.4 Cpc Scientific Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.5.5 Cpc Scientific Recent Developments9.6 Creative Peptides
9.6.1 Creative Peptides Company Information, Head Office, Market Area and Industry Position
9.6.2 Creative Peptides Company Profile and Main Business
9.6.3 Creative Peptides Peptide CDMO Pharmaceutical Models, Specifications and Application
9.6.4 Creative Peptides Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.6.5 Creative Peptides Recent Developments
9.7 Chinese Peptide
9.7.1 Chinese Peptide Company Information, Head Office, Market Area and Industry Position
9.7.2 Chinese Peptide Company Profile and Main Business
9.7.3 Chinese Peptide Peptide CDMO Pharmaceutical Models, Specifications and Application
9.7.4 Chinese Peptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.7.5 Chinese Peptide Recent Developments
9.8 Csbio
9.8.1 Csbio Company Information, Head Office, Market Area and Industry Position
9.8.2 Csbio Company Profile and Main Business
9.8.3 Csbio Peptide CDMO Pharmaceutical Models, Specifications and Application
9.8.4 Csbio Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.8.5 Csbio Recent Developments
9.9 Corden Pharma
9.9.1 Corden Pharma Company Information, Head Office, Market Area and Industry Position
9.9.2 Corden Pharma Company Profile and Main Business
9.9.3 Corden Pharma Peptide CDMO Pharmaceutical Models, Specifications and Application
9.9.4 Corden Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.9.5 Corden Pharma Recent Developments9.10 Polypeptide
9.10.1 Polypeptide Company Information, Head Office, Market Area and Industry Position
9.10.2 Polypeptide Company Profile and Main Business
9.10.3 Polypeptide Peptide CDMO Pharmaceutical Models, Specifications and Application
9.10.4 Polypeptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.10.5 Polypeptide Recent Developments
9.11 Hybio Pharmaceutical
9.11.1 Hybio Pharmaceutical Company Information, Head Office, Market Area and Industry Position
9.11.2 Hybio Pharmaceutical Company Profile and Main Business
9.11.3 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Models, Specifications and Application
9.11.4 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.11.5 Hybio Pharmaceutical Recent Developments
9.12 Peptide Institute
9.12.1 Peptide Institute Company Information, Head Office, Market Area and Industry Position
9.12.2 Peptide Institute Company Profile and Main Business
9.12.3 Peptide Institute Peptide CDMO Pharmaceutical Models, Specifications and Application
9.12.4 Peptide Institute Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.12.5 Peptide Institute Recent Developments
9.13 Pepscan
9.13.1 Pepscan Company Information, Head Office, Market Area and Industry Position
9.13.2 Pepscan Company Profile and Main Business
9.13.3 Pepscan Peptide CDMO Pharmaceutical Models, Specifications and Application
9.13.4 Pepscan Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.13.5 Pepscan Recent Developments
9.14 Almac
9.14.1 Almac Company Information, Head Office, Market Area and Industry Position
9.14.2 Almac Company Profile and Main Business
9.14.3 Almac Peptide CDMO Pharmaceutical Models, Specifications and Application
9.14.4 Almac Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.14.5 Almac Recent Developments
9.15 Vivitide
9.15.1 Vivitide Company Information, Head Office, Market Area and Industry Position
9.15.2 Vivitide Company Profile and Main Business
9.15.3 Vivitide Peptide CDMO Pharmaceutical Models, Specifications and Application
9.15.4 Vivitide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.15.5 Vivitide Recent Developments
9.16 Creosalus Inc
9.16.1 Creosalus Inc Company Information, Head Office, Market Area and Industry Position
9.16.2 Creosalus Inc Company Profile and Main Business
9.16.3 Creosalus Inc Peptide CDMO Pharmaceutical Models, Specifications and Application
9.16.4 Creosalus Inc Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.16.5 Creosalus Inc Recent Developments
9.17 Scinopharm
9.17.1 Scinopharm Company Information, Head Office, Market Area and Industry Position
9.17.2 Scinopharm Company Profile and Main Business
9.17.3 Scinopharm Peptide CDMO Pharmaceutical Models, Specifications and Application
9.17.4 Scinopharm Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.17.5 Scinopharm Recent Developments
9.18 Senn Chemicals
9.18.1 Senn Chemicals Company Information, Head Office, Market Area and Industry Position
9.18.2 Senn Chemicals Company Profile and Main Business
9.18.3 Senn Chemicals Peptide CDMO Pharmaceutical Models, Specifications and Application
9.18.4 Senn Chemicals Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.18.5 Senn Chemicals Recent Developments
9.19 Belyntic
9.19.1 Belyntic Company Information, Head Office, Market Area and Industry Position
9.19.2 Belyntic Company Profile and Main Business
9.19.3 Belyntic Peptide CDMO Pharmaceutical Models, Specifications and Application
9.19.4 Belyntic Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.19.5 Belyntic Recent Developments9.20 Ferring Pharma
9.20.1 Ferring Pharma Company Information, Head Office, Market Area and Industry Position
9.20.2 Ferring Pharma Company Profile and Main Business
9.20.3 Ferring Pharma Peptide CDMO Pharmaceutical Models, Specifications and Application
9.20.4 Ferring Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.20.5 Ferring Pharma Recent Developments
9.21 Numaferm
9.21.1 Numaferm Company Information, Head Office, Market Area and Industry Position
9.21.2 Numaferm Company Profile and Main Business
9.21.3 Numaferm Peptide CDMO Pharmaceutical Models, Specifications and Application
9.21.4 Numaferm Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.21.5 Numaferm Recent Developments
9.22 Hybio Pharmaceutical
9.22.1 Hybio Pharmaceutical Company Information, Head Office, Market Area and Industry Position
9.22.2 Hybio Pharmaceutical Company Profile and Main Business
9.22.3 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Models, Specifications and Application
9.22.4 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.22.5 Hybio Pharmaceutical Recent Developments
9.23 Provepharm Life Solutions
9.23.1 Provepharm Life Solutions Company Information, Head Office, Market Area and Industry Position
9.23.2 Provepharm Life Solutions Company Profile and Main Business
9.23.3 Provepharm Life Solutions Peptide CDMO Pharmaceutical Models, Specifications and Application
9.23.4 Provepharm Life Solutions Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.23.5 Provepharm Life Solutions Recent Developments
9.24 Enzene Biosciences
9.24.1 Enzene Biosciences Company Information, Head Office, Market Area and Industry Position
9.24.2 Enzene Biosciences Company Profile and Main Business
9.24.3 Enzene Biosciences Peptide CDMO Pharmaceutical Models, Specifications and Application
9.24.4 Enzene Biosciences Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.24.5 Enzene Biosciences Recent Developments
9.25 Piramal Pharma
9.25.1 Piramal Pharma Company Information, Head Office, Market Area and Industry Position
9.25.2 Piramal Pharma Company Profile and Main Business
9.25.3 Piramal Pharma Peptide CDMO Pharmaceutical Models, Specifications and Application
9.25.4 Piramal Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024
9.25.5 Piramal Pharma Recent Developments
10 Conclusion
11 Appendix11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources11.3 Market Estimation Model
11.4 Disclaimer
-
The Peptide CDMO Pharmaceutical Global and China Top Players Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.
Report Objectives / Segmentation Covered :
By Companies / players:
By Regions:
By Type:
By Application:
Frequently asked questions(FAQ's):
Recognize the areas along the Peptide CDMO Pharmaceutical Global and China Top Players Market's value chain where players are generating value. To get a complete picture, kindly read the entire report.
According to the report, the Peptide CDMO Pharmaceutical Global and China Top Players Industry will grow to USD XXX Million by 2029, with a YY% CAGR.
Consumer behavior changes will reshape the entire decision-making process and companies in the Peptide CDMO Pharmaceutical Global and China Top Players Industry will need to adapt quickly.
In this highly competitive and rapidly evolving Peptide CDMO Pharmaceutical Global and China Top Players Industry, top strategic priorities such as innovation, diversification, and M&A would remain consistent.
